Overview

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Status:
Not yet recruiting

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.

Phase:

Phase 3

Details

Lead Sponsor:

Myovant Sciences GmbH

Treatments:

Relugolix